Primary AML cells (n = 20; ELN 2022 risk: 3 favorable; 3 intermediate; 14 adverse) were also treated with 50 nM daunorubicin in combination with AR blockers in the presence of DHT. This evidence concerns the gene AR and acute myeloid leukemia.